How can they develop technology with only 7 employees?
Please answer this question, I already showed proof that the number of employees is that limited.

Total assets: +21M dollar!!!
Total assets > total liabililities: +21M > 19M
Total stockholders equity is POSITIVE! : +/- 3M dollar
Net income is POSITIVE: pro forma: 550,280 dollar
Income per share is POSITIVE: 0.004 dollar

More revenues will be made when cosmetics get sold in the US!

Purely talking about the balance: this is a great opportunity to get in.

Talking medically: innovative cosmetics (stem cell to look younger, less painful way for hair growth) and stem cell research by a big mondial player namely Hirostem: this is a great opportunity to get in.

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7206448

Thank you.

@moderator: could you sticky my last post please?

Updates: CytoSorbents Executive Summary -June 2010 and CytoSorbents Company Presentation -June 2010

http://02c390e.netsolhost.com/invest.htm

keywords:
limited competition (only Xigris is approved to treat sepsis, but has questionable efficacy and safety)
critical care play and therefore an easy market penetration
reimbursement friendly
high margin disposable device in an under-served multi-billion dollar market with strategically important technology



The Company has leading, patented technology backed by strong science and a highly profitable business model. We believe CytoSorb™ has the potential to be a blockbuster therapy that can be sold throughout the world as a treatment for sepsis and other diseases exacerbated by cytokine storm. If successful, these characteristics position the Company well for growth and future value creation for shareholders. Also, we continue to unlock the value of our underlying polymer platform technology through the ability to modify it for other medical applications, further broadening our pipeline and potential for out-licensing opportunities.

When the Q-report comes out, we will probably see the numbers of patients already enrolled. Could possibly be a trigger to test the 52 week high (0.44) again.

At this moment, nor in the past, I don't have a position in this stock. I admit that it fascinates me, but the facts in the annual report keep my feet on the ground.
No revenues, only 7 employees and no big institutions holding shares. I'm sure Virgin airlines would have bought a position in the company if the technology was that promissing...

Oh yes, mundus group forgot to mention one other company who is developping vertical launched vehicles; they forgot to mention lightcraft technologies which is a private holding company.

Outsourcing would be written as "payroll expenses" in the annual report. So, honestly do you think there would be more than 7 employees/people working for the company when you see the payroll expense of 100,009.95 dollar ?

100,009.95 dollar : 7 = 14287.135 dollar
14287.135 dollar : 12 = 1190 dollar/ month for each of the 7 employees...
In summary: poor employees, poor company, rich CEO, scam stock

They have only 7 employees according to pinksheets:
http://www.otcmarkets.com/stock/MNDP/company-info

That could be very much true accoring to the annual report:
expense: payroll expenses: 100,009.95 dollar
page 10
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById.pdf?id=31473

For this technology they only have 7 employees??!! Looks like this is a total scam.

when is the FDA evaluating phase 3 on restanza?

MM's at the ask:
HDSN: 0.06
LABS: 0.335
VFIN: 0.63
VERT: 0.79
...

That means that only 1 MM is at this price level while the other ones value the share price a lot higher.

Ask price is 0.08dollar/share... For those who want to get in or buy some more shares, I don't think you will get any shares lower than that.

It is excellent public relations for the product doing these clinical trials. The participants will be happy, and if they can show objective, positive study results comfirmed by the FDA, there will be a lot more women buying this product.

"Participants in the consumer-based study will use SteMixx™ exclusively for a month and provide subjective data on efficacy, product characteristics and satisfaction. The data will be used to support AmStem's ongoing marketing campaigns for the full launch of SteMixx™ sales in high-end e-commerce, retail and wholesale markets next quarter."

http://finance.yahoo.com/news/AmStem-Announces-Initial-US-iw-1363909465.html?x=0&.v=1

And I have to say the cosmetical products amstem corp offers, look very classy too. Which is important for customers.

Indeed, this company has an enormous potential and even an institutional holder:
http://finance.yahoo.com/q/mh?s=CSKH.OB+Major+Holders

They have a top institutional holder: Pacific West Financial Consultants, Inc

http://finance.yahoo.com/q/mh?s=AMST.OB+Major+Holders

I am in with 10K (5K at 0.056 and 0.058).

RT 0.104 dollar/share

It comes all to the money for investors. I'm comparing this stock with other stocks from the market in general.
Nevertheless I would like to spend some money on a stem cell company like this. But as for now, the price per share is overpriced. IMO

I know a lot of stock being played down by the market:
CHIO, ULU, NWBO, ...

That is what I know, and that is what will happen with amst for the next couple of days or weeks, until significant news arrives...

Never said that I didn't want to own amstem. But as for now this is way overbought. You will see I'm right.

Until there will be a new PR this is a falling knife.

So down again. Let me gues what will happen tomorrow.

Can somebody update me about the company?
1. Current number of O/S and A/S
2. Is there any FDA news to be expected soon?

Because the PR was not very clear.

Well, I would love to see an auditor estimate the current assets. I'm sure they would be worth a lot less, then what there is reported now.

IMO you can buy as much as you want now, but I'm pretty sure I will be able to get in lower. It's overbought now.
(I'm not talking about midlong term, but I'm talking about the present.)

"In addition the Company is a defendant in four other lawsuits arising in the ordinary course of business. The Company is unable to predict the possible outcome of such litigations. However, in the opinion of management, the ultimate disposition of these matters will not have a material adverse effect on the Company’s financial position, results of operations, or liquidity."

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7206448

Table of contents F-20: 16.Contingencies

"The sale or issuance of a substantial number of shares may adversely affect the market price for our common stock.


The future sale of a substantial number of shares of our common stock in the public market, or the perception that such sales could occur, could significantly and negatively affect the market price for our common stock. We expect that we will likely issue a substantial number of shares of our capital stock in financing transactions in order to fund our operations and the growth of our business. Under these arrangements, we may agree to register the shares for resale soon after their issuance. We may also continue to pay for certain goods and services with equity, which
would dilute our current stockholders. Also, sales of the shares issued in this manner could negatively affect the market price of our stock."

http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=7206448
p37

According to their last Q-filing there are too much liabilities and current debt to comply with at PPS of this level.
You are right about the creams and all, the stock has potential, but the company needs to fulfill this potential first. This is now and at this point I would say a PPS of 0.02-0.04 would be more in line with the current true value of the company.

Topeka station still operational.
http://www.topekagasprices.com/index.aspx?fuel=A&station=Evolution%20Fuels&dl=Y&intro=Y

Rockcat added the new prices 15 hours ago.

That is why pps will make a correction downwards after the weekend. Investors want to see the cream in the US first before the share price can actually move upward substantially IMO.

The bids at 0.040 and 0.044 are solid.

I have a bid at 0.025

Pipeline opportunities:

IMO when they have the CE mark approval, they will be able to use these revenues partially for a) trials in the US and b) for clinical trials for the rest of their pipeline which is quite impressive:

1) betasorb: improvement of hemodialysis in end-stage renal disease
2) cytosorb (other than sepsis treatment): cardiopulmonary bypass + organ transplant + influenza
3) CST 101: drug overdose + chemical exposure or intoxication
4) CST 201: chemotherapy removal
5) CST 301: removal of myoglobin from blood caused by muscle breakdown and trauma

http://www.cytosorbents.com/pdf/CytoSorbents_Investor_Executive_Summary_September_2009_Final_090309.pdf
page 3

Nice to read your disclaimer: "I am short".

Mine is "I am long".
I stronly believe in this company and its' potential.

This is the prelude of other institutional investors buying in.
IMO

www.in3east.com

"The Main Event is designed for those in the business development and/or financial community who are interested in investment or partnering opportunities with medtech innovators. Medtech innovators give 10-minute presentations on their latest medical device innovations within a wide range of high-growth markets. In between presentation blocks, enjoy dedicated break-out sessions for one-on-one meetings, and networking."

Look at: presenting start-ups
"CytoSorbents, Inc.
CytoSorb™ is a proprietary blood purification resin in clinical trials to treat severe sepsis or “overwhelming infection” by reducing cytokine storm; a major cause of organ failure and death in sepsis."

GREAT opportunity

I advise you all to look at the website:
http://www.in3east.com/content/Main.aspx

"The Main Event is designed for those in the business development and/or financial community who are interested in investment or partnering opportunities with medtech innovators. Medtech innovators give 10-minute presentations on their latest medical device innovations within a wide range of high-growth markets. In between presentation blocks, enjoy dedicated break-out sessions for one-on-one meetings, and networking."

Look at: presenting start-ups
"CytoSorbents, Inc.
CytoSorb™ is a proprietary blood purification resin in clinical trials to treat severe sepsis or “overwhelming infection” by reducing cytokine storm; a major cause of organ failure and death in sepsis."

GREAT opportunity

PTSH is part of the minamargroup and they're corrupt IMO.

" ... However, unlike survival and durable response, these early endpoints are not established for regulatory purposes as demonstrating clinical benefit in this population. We expect to complete the blinded followup for overall survival and durable response from AGENDA in the first quarter of 2011, and we look forward to those results.”

First quarter of 2011...
But first things first: bridging the period until Q1 2011 implies a solid R/S.

ASK at 0.10$/share that is just awesome! Another sign to keep your shares tight.

I saw exactly the same post on yahoo...